Wendy Hill has over 20 years experience in clinical development and regulatory affairs in a variety of therapeutic areas including cancer, inflammation, infectious and cardiovascular disease. She has played a key role in preparing the clinical plan and protocols for PDC's lead candidate. Previous positions include Director of Research at Knoll Canada, Senior Director, Clinical Research at GlycoDesign and R&D Director, Inflammation and Neurology at Amgen Canada. Since founding Gap Strategies in the spring of 2004, she has been assisting biotechnology companies prepare and execute strategic clinical and regulatory development plans for products and devices.

Monika Chabicovsky founded MC Toxicology Consulting, a Vienna based Consulting Company, in 2006. Her company's core expertise comprises the non-clinical development of biologics and small molecules focusing primarily on toxicology related questions and regulatory affairs.

Monika holds a PhD in cancer research from the University of Vienna, a Master in Toxicology and a Diploma in Regulatory Affairs (University of Cardiff).

Christian Soschner, Mag. (MBA), has been in the finance business for over 11 years. Previously he headed and built up the finance & controlling department at Nabriva, an Austrian biotech company, responsible for strategic business planning, reporting, annual financial statements, risk management, treasury and contracting. Prior to this he held management positions in the finance area at Agrana, Atos Origin, Austrian Post and NPOs. He holds a degree in economics from the University of Economy, Graz and is certified Management Coach and Martial Arts Trainer.

Bernhard Fischer is President of Biotechnology Consulting, a company which provides consulting services to the international life science biotechnology and pharmaceutical industry.

In the course of his career he headed senior management positions in biopharmaceutical research and development, regulatory affairs, chemistry manufacturing & controls documentation and technical drug development. During his professional development he has been research biochemist at the Institute of Molecular Biology and Institute of Biotechnology in Germany, Higher Scientific Officer at the Department of Protein Engineering of the AFRC in the United Kingdom, Head of the Department of Recombinant Proteins at the Biomedical Research Center of BAXTER in Austria, Manager Chemistry Manufacturing & Controls and Manager Regulatory Affairs at SANDOZ (Novartis) in Austria, Chief Technical Officer at AVIDIS in France, Vice President Development and Chief Technical Officer at FIBREX MEDICAL in Austria.

Dr. Fischer is an Associate Professor (Universitäts-Dozent) for Protein Chemistry at the University of Applied Life Sciences in Vienna, and lecturer in the fields of medicinal drug development and regulatory affairs at various academic organizations.

Jean-René Kiechel, PhD, has over 30 years experience in Pharmaceutical R & D, in various scientific management positions in Switzerland, USA and France with Sandoz, Bristol-Myers Squibb, Rhone-Poulenc Rorer and Aventis. His main areas of research interest and contributions have been drug metabolism and pharmacokinetics, new drug delivery systems, including nasal and pulmonary delivery, quinolones and early discovery to development transfer. In the course of his career, Dr. Kiechel has served as an Expert for the French Ministry of Health as well as for Sub-Committees of the European Commission. He has been member of various scientific committees and a consultant for start-ups and early development projects. He has also been involved in technology platform and portfolio assessments and has contributed to the success of half a dozen Registrations and the preparation of several IND's.

Since 2002, Dr. Kiechel has been the International Project Manager of the Malaria projects For DNDi (Drug for Neglected Disease initiative) a Geneva based humanitarian organisation , where he has led , the development of two Artesunate based Fixed Dose Combinations, which were successfully registered in 2007 and 2008 respectively.

Dr. Kiechel holds a PhD in Chemistry and a Diploma in Pharmacology from the University of Basel in Switzerland. He extended his training in Clinical Pharmacology (UK and USA) and Management (INSEAD, France).